JFJohan Frans

Johan Frans

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Johan Frans has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Annick Smismans

    From the Departments of Radiology (C.G., A. Dangis, L.J., A. Demeyere, Y.D.B., R.S.), Pulmonology (N.D.B., A.v.d.B., T.L., A.H., E.F.), Intensive Care Medicine (E.F.), Geriatrics (M.L.), Cardiology (B.E., J.R.), Medical Microbiology (A.S., J.F.), and Emergency Medicine (M.G.), Imelda Hospital, Imeldalaan 9, 2820 Bonheiden, Belgium

    4 shared publications
  • Michaël R. Laurent

    Geriatrics Department, Imelda Hospital, Bonheiden, Belgium

    4 shared publications
  • Rolf Symons

    Radiology and Imaging Sciences - National Institutes of Health Clinical Center, Bethesda, MD, USA

    4 shared publications
  • Annick Demeyere

    From the Departments of Radiology (C.G., A. Dangis, L.J., A. Demeyere, Y.D.B., R.S.), Pulmonology (N.D.B., A.v.d.B., T.L., A.H., E.F.), Intensive Care Medicine (E.F.), Geriatrics (M.L.), Cardiology (B.E., J.R.), Medical Microbiology (A.S., J.F.), and Emergency Medicine (M.G.), Imelda Hospital, Imeldalaan 9, 2820 Bonheiden, Belgium

    2 shared publications
  • Anthony Dangis

    From the Departments of Radiology (C.G., A. Dangis, L.J., A. Demeyere, Y.D.B., R.S.), Pulmonology (N.D.B., A.v.d.B., T.L., A.H., E.F.), Intensive Care Medicine (E.F.), Geriatrics (M.L.), Cardiology (B.E., J.R.), Medical Microbiology (A.S., J.F.), and Emergency Medicine (M.G.), Imelda Hospital, Imeldalaan 9, 2820 Bonheiden, Belgium

    2 shared publications
  • Christopher Gieraerts

    From the Departments of Radiology (C.G., A. Dangis, L.J., A. Demeyere, Y.D.B., R.S.), Pulmonology (N.D.B., A.v.d.B., T.L., A.H., E.F.), Intensive Care Medicine (E.F.), Geriatrics (M.L.), Cardiology (B.E., J.R.), Medical Microbiology (A.S., J.F.), and Emergency Medicine (M.G.), Imelda Hospital, Imeldalaan 9, 2820 Bonheiden, Belgium

    2 shared publications

Latest Publications

  • Open Access

    Monitors to Improve Indoor Carbon Dioxide Concentrations in the Hospital: Background, Rationale and Protocol for a Randomized, Sham-controlled, Cross-Over, Open Label Trial

    by Michaël R. Laurent, Johan Frans

    Coronavirus disease 2019 (COVID-19) has caused considerably morbidity and mortality worldwide, mainly among older adults. Hospital outbreaks contribute to the burden of this disease, despite optimal hand hygiene and personal protective equipment such as masks and face shields. Ventilation with fresh outdoor air has emerged as an important strategy to reduce indoor aerosol transmission of COVID-19. Carbon dioxide (CO 2 ) monitors are increasingly advocated to facilitate ventilation in schools, long-term care facilities, offices and public buildings. Moreover, several health authorities have issued guidelines for target CO 2 values in work as well as clinical environments. Given that modern hospitals have superior indoor air quality control systems, it remains however unknown whether feedback from CO 2 monitors is needed and/or effective to improve ventilation further. Here, we describe the rationale and protocol for a randomized, sham-controlled, crossover, open label trial of CO 2 monitors in double-bed hospital rooms in two acute geriatric wards. Based on pilot data, Aranet4 Home ® monitors will be used to alert nurses and other staff to raised indoor CO 2 concentrations. Practical limitations in implementing CO 2 monitors are discussed, and will be surveyed among staff as additional study outcomes. The Monitors to Improve Indoor Carbon Dioxide (CO 2 ) Concentrations in the Hospital (MICH) trial is registered at ClinicalTrials.gov, identifier: NCT04770597 .

  • Prognostic Value and Reproducibility of AI-assisted Analysis of Lung Involvement in COVID-19 at Low-Dose Submillisievert Chest CT: Sample Size Implications for Clinical Trials

    by Christopher Gieraerts, Anthony Dangis, Lode Janssen, Annick Demeyere, Yves De Bruecker, Nele De Brucker, Annelies van Den Bergh, Tine Lauwerier, André Heremans, Eric Frans, et al.

    To compare the prognostic value and reproducibility of visual versus AI-assisted analysis of lung involvement on submillisievert low-dose chest CT in COVID-19 patients. This was a HIPAA-compliant, institutional review board-approved retrospective study. From March 15 to June 1, 2020, 250 RT-PCR confirmed COVID-19 patients were studied with low-dose chest CT at admission. Visual and AI-assisted analysis of lung involvement was performed by using a semi-quantitative CT score and a quantitative percentage of lung involvement. Adverse outcome was defined as intensive care unit (ICU) admission or death. Cox regression analysis, Kaplan-Meier curves, and cross-validated receiver operating characteristic curve with area under the curve (AUROC) analysis was performed to compare model performance. Intraclass correlation coefficients (ICCs) and Bland- Altman analysis was used to assess intra- and interreader reproducibility. Adverse outcome occurred in 39 patients (11 deaths, 28 ICU admissions). AUC values from AI-assisted analysis were significantly higher than those from visual analysis for both semi-quantitative CT scores and percentages of lung involvement (all P<0.001). Intrareader and interreader agreement rates were significantly higher for AI-assisted analysis than visual analysis (all ICC ≥0.960 versus ≥0.885). AI-assisted variability for quantitative percentage of lung involvement was 17.2% (coefficient of variation) versus 34.7% for visual analysis. The sample size to detect a 5% change in lung involvement with 90% power and an α error of 0.05 was 250 patients with AI-assisted analysis and 1014 patients with visual analysis. AI-assisted analysis of lung involvement on submillisievert low-dose chest CT outperformed conventional visual analysis in predicting outcome in COVID-19 patients while reducing CT variability. Lung involvement on chest CT could be used as a reliable metric in future clinical trials.


  • Frailty and Mortality in Hospitalized Older Adults With COVID-19: Retrospective Observational Study

    by Robert De Smet, Bea Mellaerts, Hannelore Vandewinckele, Peter Lybeert, Eric Frans, Sara Ombelet, Wim Lemahieu, Rolf Symons, Erwin Ho, Johan Frans, et al.


  • Open Access

    Frailty and mortality in hospitalized older adults with COVID-19: retrospective observational study

    by Robert De Smet, Bea Mellaerts, Hannelore Vandewinckele, Peter Lybeert, Eric Frans, Sara Ombelet, Wim Lemahieu, Rolf Symons, Erwin Ho, Johan Frans, et al.

    Background: Older adults with coronavirus disease 2019 (COVID-19) face an increased risk of adverse health outcomes including mortality. Ethical guidelines consider allocation of limited resources based on likelihood of survival, frilty, co-morbidities and age. However, the association of frailty with clinical outcomes in older COVID-19 patients remains unclear. Objectives: To determine the association between frailty and short-term mortality in older adults hospitalized for COVID-19. Design: Retrospective single-center observational study. Setting and participants: N = 81 patients with COVID-19 confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR), at the Geriatrics department of Imelda general hospital, Belgium. Measurements: Frailty was graded according to the Rockwood Clinical Frailty Scale (CFS). Demographic, biochemical and radiological variables, co-morbidities, symptoms and treatment were extracted from electronic medical records. Results: Participants (N = 48 women, 59%) had a median age of 85 years (range 65-97 years), median CFS score of 7 (range 2 - 9), and 42 (52%) were long-term care residents. Within six weeks, eighteen patients died. Mortality was significantly but weakly associated with age (Spearman r = 0.241, P = 0.03) and CFS score (r = 0.282, P = 0.011), baseline lactate dehydrogenase (LDH) (r = 0.301, P = 0.009), lymphocyte count (r = -0.262, P = 0.02) and RT-PCR Ct value (r = -0.285, P = 0.015). Mortality was not associated with long-term care residence, dementia, delirium or polypharmacy. In multivariable logistic regression analyses, CFS, LDH and RT-PCR Ct values (but not age) remained independently associated with mortality. Both age and frailty had poor specificity to predict survival. A multivariable model combining age, CFS, LDH and viral load significantly predicted survival. Conclusions and implications: Although their prognosis is worse, even the oldest and most severely frail patients may benefit from hospitalization for COVID-19, if sufficient resources are available. BRIEF SUMMARY: Outcomes of frail older adults hospitalized for COVID-19, particularly long-term care residents, remain unclear. In this retrospective cohort, frailty predicted mortality independently of age or established biomarkers.


  • Accuracy and Reproducibility of Low-Dose Submillisievert Chest CT for the Diagnosis of COVID-19

    by Anthony Dangis, Christopher Gieraerts, Yves De Bruecker, Lode Janssen, Hanne Valgaeren, Dagmar Obbels, Marc Gillis, Marc Van Ranst, Johan Frans, Annick Demeyere, et al.

    Purpose To demonstrate the accuracy and reproducibility of low-dose submillisievert chest CT for the diagnosis of COVID-19 infection in emergency room (ER) patients. Materials and Methods This was ...


  • First case of Candida auris infection in Belgium in a surgical patient from Kuwait

    by Klaas Dewaele, Johan Frans, Annick Smismans, Erwin Ho, Tim Tollens, Katrien Lagrou

    Objective and importance: Candida auris is a relatively new yeast species and an emerging opportunistic pathogen. It was first reported in 2009 in East Asia, as a difficult-to-identify Candida species of uncertain clinical relevance. In recent years, it has appeared globally as a cause of invasive infections, not infrequently eliciting nosocomial outbreaks. Species identification in clinical laboratories has been challenging, as traditional phenotypic and biochemical methods have been generally unreliable. Clinical management is often complicated by multidrug resistance in many isolates. Additionally, C. auris has demonstrated an unusual ability for persistence in the hospital environment and in asymptomatic patients. We present the first Belgian case of C. auris infection along with a brief review of the literature.Clinical presentation: A patient was referred from Kuwait for surgical treatment after a complicated bariatric procedure. Few days after transferral, she developed a catheter-related blood stream infection with C. auris. We obtained a low-confidence identification of C. auris with the Bruker Biotyper MALDI-TOF MS system (Bruker Corporation, Billerica, MA, U.S.A.), and of Candida haemulonii with the Vitek YST identification system, version 7.01 (bioMérieux, Marcy-L’Etoile, France). Definite identification was obtained using Internal Transcribed Spacer (ITS) sequencing. As most C. auris isolates, our strain was resistant to fluconazole, and the patient was eventually treated with catheter removal and anidulafungin therapy. We documented persistence of C. auris clones with acquired echinocandin resistance in our patient up to 18 months after the infection.Conclusion: Clinicians and microbiologists should be aware of this globally emerging yeast, that poses important challenges in identification, treatment and hospital infection control.


  • OPAT: proof of concept in a peripheral Belgian hospital after review of the literature

    by Annick Smismans, Astrid Vantrappen, Freija Verbiest, Christophe Indevuyst, Bea Van Den Poel, Sandrina von Winckelmann, Annelore Peeters, Sara Ombelet, Peter Lybeert, Andre Heremans, et al.

    Since its introduction in the 1970s in the United States, outpatient parenteral antibiotic/antimicrobial therapy (OPAT) has been adopted internationally for long-term intravenous (IV) treatment of stable infectious diseases. The aim is to provide a safe and successful completion of IV antimicrobial treatment at the ambulatory care center or at home without complications and costs associated with hospitalization. OPAT implementation has been accelerated by progress in vascular access devices, newly available antibiotics, the emphasis on cost-savings, as well as an improved patient comfort and a reduced incidence of health care associated infections with a similar outcome. OPAT utilization is supported by an extensive published experience and guidelines of the British Society of Antimicrobial Chemotherapy and the Infectious Diseases Society of America for adults as well as for children. Despite these recommendations and its widespread adoption, in Belgium OPAT is only fully reimbursed and established for cystic fibrosis patients. Possible explanations for this unpopularity include physician unfamiliarity and a lack of uniform funding arrangements with higher costs for the patient. This article aims to briefly review benefits, risks, indications, financial impact for supporting OPAT in a non-university hospital as standard of care. Our experience with OPAT at the ambulatory care center of our hospital and its subsequent recent introduction in the home setting is discussed.


  • Su1186 Clinical Comparison of Eight Different Calprotectin Immunoassays for the Diagnosis and Follow-up of Inflammatory Bowel Disease

    by Delphine Labaere, Annick Smismans, August Van Olmen, Paul Christiaens, Geert R. D'Haens, Veerle Moons, Pieter-Jan A. Cuyle, Johan Frans, Peter Bossuyt